Hormonal contraception with progestagen desogestrel in women with diffuse non-toxic goiter аnd autoimmune thyroiditis

Galina Petrovna Pologoyko , Maria Igorivna Yarmolinskaya , Tatyana Mihajlovna Lekareva

Journal of obstetrics and women's diseases ›› 2013, Vol. 62 ›› Issue (6) : 40 -46.

PDF
Journal of obstetrics and women's diseases ›› 2013, Vol. 62 ›› Issue (6) : 40 -46. DOI: 10.17816/JOWD62640-46
Articles
research-article

Hormonal contraception with progestagen desogestrel in women with diffuse non-toxic goiter аnd autoimmune thyroiditis

Author information +
History +
PDF

Abstract

The article represents influence of gestagen desogestrel on size and function of thyroid gland in women of reproductive age. Into the study we included 70 women who were prescribed gestagen desogestrel in a daily dose of 75 mg for a period of 12 months. All the patients were devided into two groups. The first group consisted of 20 women with diffuse nontoxic goiter, the second consisted of 30 women with autoimmune thyroiditis. Control group consisted of 20 women without thyroid gland pathology. Prior to therapy with desogestrel and after 12 month of treatment, serum levels of free triiodothyronine, free thyroxine and thyrotropin releasing hormone, thyroperoxidase antibodies were determined and thyroid gland sonigraphy was performed in all the patients. Obtained data show that gestagen desogestrel doesn’t influence the size and function of thyroid gland in healthy women and in patients with diffuse non-toxic goiter. In women with autoimmune thyroiditis implication of desogestrel significantly decreases blood levels of thyroperoxidase autoantibodies.

Keywords

diffuse non-toxic goiter / autoimmune thyroiditis / hormonal contraception

Cite this article

Download citation ▾
Galina Petrovna Pologoyko, Maria Igorivna Yarmolinskaya, Tatyana Mihajlovna Lekareva. Hormonal contraception with progestagen desogestrel in women with diffuse non-toxic goiter аnd autoimmune thyroiditis. Journal of obstetrics and women's diseases, 2013, 62(6): 40-46 DOI:10.17816/JOWD62640-46

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Акопян А. Н. Функция репродуктивной системы и гормональная контрацепция у женщин с аутоиммунным тиреоидитом. Гинекология. 2008. 10 (5): 8-15.

[2]

Акопян А. Н., Зиганшина М. М., Кречетова Л. B., Менжинская И. В., Сухих Г. Т., Межевитинова Е. А. Контрацепция у женщин с аутоиммунной патологией. Акушерство и гинекология. 2009; 5: 48-51.

[3]

Дедов И. И., Трошина Е. А., Юшков П. В., Александрова Г. Ф. Диагностика и лечение узлового зоба. Петрозаводск: Интел Тек; 2003.

[4]

Коган И. Ю., Мусина Е. В. Гестагенные контрацептивы и мастопатия. Журнал акушерства и женских болезней. 2009; LVIII (6): 70-5.

[5]

Корхов В. В. Медицинские аспекты применения контрацептивных препаратов. СПб.; 1996.

[6]

Межевитинова Е. А. Прогестагены в контрацепции. Гинекология. 2001; 2: 36-40.

[7]

Мельниченко Г. А., Фадеев В. В., Дедов И. И. Заболевания щитовидной железы во время беременности. Диагностика, лечение, профилактика: пособие для врачей. М.: МедЭкспертПресс; 2003.

[8]

Потин В. В., Логинов А. Б., Крихели И. О., Мусаева Т. Т., Ткаченко Н. Н., Шелаева Е. В. Щитовидная железа и репродуктивная система женщины: пособие для врачей. СПБ.: Изд-во Н-Л; 2008.

[9]

Тарасова М. А., Шаповалова К. А., Лекарева Т. М. Консультирование по вопросам репродуктивного здоровья и выбору метода контрацепции. СПб.: Изд-во Н-Л; 2008.

[10]

Фадеев В. В. Йоддефицитные и аутоиммунные заболевания щитовидной железы в регионе легкого йодного дефицита. Автореф.дис. д-ра мед. наук. М., 2004.

[11]

Banu K. S., Govindarajulu P., Aruldhas M. M. Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. Endocr. Pathol. 2001; 12 (3): 315-27.

[12]

Brunn J. et al. Volumetrie der Schiddriise mittels Real time-Sonogrophie. Dtsch. Med. Wochenschr. 1981; 106: 1338-40.

[13]

Domoslawski P., Podhorska-Okolow M., Pula B. et al. Expression of estrogen and progesterone receptors and Ki-67 antigen in Graves’ disease and nodular goiter. Folia Histochem. Cytobiol. 2013; 51 (2): 135-40.

[14]

Frank Z. S. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Reviews Endocr. Metabolic. Disorders. 2002; 3 (3): 211-24.

[15]

Gellersen B., Brosens I. A., Brosens J. J. Non-genomic progesterone actions in female reproduction. Hum. Reprod. Update. 2009; 15: 119-38

[16]

Gellersen J. J., Hodgetts A., Feroze-Zaidi F. et al. Decidualization of the human endometrium: mechanisms, functions, and clinical perspectives. Semin. Reprod. Med. 2007; 25: 445-53.

[17]

Olsson S. E., Wide L., Odlind V. Aspects of thyroid function during use Norplant implants. Contraception. 1986; 34: 583-7.

[18]

Van Hylckama V. A., Helmerhorst F. M., Vandenbroucke J. P. et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. Br. Med. J. 2009; 13: 339-42.

[19]

Wilder R. L. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J. Rheumatol. 1996; 44 (Suppl.): 10-2.

RIGHTS & PERMISSIONS

Pologoyko G.P., Yarmolinskaya M.I., Lekareva T.M.

AI Summary AI Mindmap
PDF

114

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/